Marie Curie's wealth gap comes down to one fundamental choice: she rejected commercialization entirely. While Einstein's estate aggressively monetized his name and image—pulling in $2M annually from licensing deals alone—Curie actively refused to patent radium or her separation techniques. She donated her discoveries to science and humanity, which is genuinely noble, but financially catastrophic. Einstein, by contrast, died in 1955 just as his brand became globally recognizable, and his executors immediately recognized the goldmine: the Einstein name could sell everything from insurance to physics textbooks. Curie had the same opportunity with radium but chose the laboratory over the ledger.

The timing and execution also mattered enormously. Einstein's estate benefited from the post-WWII explosion of consumer culture and America's intellectual property boom—his image became iconic precisely when mass media could monetize it. Curie died in 1934, during the Depression, when monetizing anything was harder. But more importantly, her refusal to patent meant she never built a defensible business moat. She discovered radium, but because she didn't own the patent, other companies commercialized it and captured billions in market value. Einstein's refrigeration patent, while never commercialized, at least existed as a legal asset that protected his intellectual portfolio. Curie's open-source approach was philosophically pure but economically naive.

Today's $7M gap is actually Einstein's "death advantage." He generated most of his wealth posthumously through carefully managed estates and licensing agreements—Hebrew University's annual $2M grab is institutional revenue engineering, not earnings from his lifetime. Curie never had that infrastructure. Had she simply patented radium and collected 1% of the global radium market from 1910-1934, she'd have been worth $500M+ in today's dollars. Instead, her scientific immortality came at a personal financial cost. The bitter irony: she could have funded her own laboratory empire and still revolutionized medicine. She chose principle over portfolio, and the wealth gap is the price of her integrity.